theory clinical_64_1
imports Main

begin

typedecl entity
typedecl event

consts
  KinaseInhibitor :: "entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  PI3KAKTPathway :: "entity ⇒ bool"
  Target :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  AlpelisibFulvestrant :: "entity ⇒ bool"
  PIK3CAMutated :: "entity ⇒ bool"
  HRPositive :: "entity ⇒ bool"
  HER2Negative :: "entity ⇒ bool"
  AdvancedBreastCancer :: "entity ⇒ bool"
  EndocrineTherapy :: "entity ⇒ bool"
  Received :: "event ⇒ bool"
  Previously :: "event ⇒ bool"
  Beneficial :: "entity ⇒ entity ⇒ bool"
  PIK3CAMutation :: "entity ⇒ bool"
  Prolong :: "event ⇒ bool"
  ProgressionFreeSurvival :: "entity ⇒ bool"
  LikelyLessSensitive :: "entity ⇒ entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  From :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. KinaseInhibitor x ∧ Mutations y ∧ PI3KAKTPathway z ∧ Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ In y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Proliferation y ∧ Survival y"

(* Explanation 2: Treatment with alpelisib–fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3. Treatment x ∧ AlpelisibFulvestrant x ∧ Agent e1 y ∧ PIK3CAMutated y ∧ HRPositive y ∧ HER2Negative y ∧ AdvancedBreastCancer y ∧ EndocrineTherapy z ∧ Received e1 ∧ Agent e1 y ∧ Patient e1 z ∧ Previously e1 ∧ Beneficial x y ∧ PIK3CAMutation w ∧ Target e2 ∧ Agent e2 x ∧ Patient e2 w ∧ Prolong e3 ∧ Agent e3 x ∧ ProgressionFreeSurvival w"

(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)
axiomatization where
  explanation_3: "∀x y e. Agent e x ∧ Chemotherapy y ⟶ LikelyLessSensitive x y"

theorem hypothesis:
  assumes asm: "Agent e x ∧ EndocrineTherapy y ∧ Received e ∧ Agent e x ∧ Patient e y ∧ Previously e"
  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)
  shows "∃x y z e1 e2. (∃e. Agent e x ∧ EndocrineTherapy y ∧ Received e ∧ Agent e x ∧ Patient e y ∧ Previously e) ⟶ (Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ From e2 z ∧ AlpelisibFulvestrant z ∧ Target e2 z)"
  sledgehammer
  oops

end
